title: Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
abstract: This paper reviews the experience of the Global Alliance for Vaccines and Immunization (GAVI) in introducing hepatitis B and Haemophilus influenzae type b vaccines in the poorest countries, and explores how financing for immunization has changed since GAVI Fund resources were made available during its first wave of support between 2000 and 2006. The analysis of Financial Sustainability Plans in 50 countries allowed for some of the original funding assumptions of the GAVI approach to be tested against the realities in a wide set of countries, and to highlight implications for future immunization efforts. While the initial GAVI experience with financial sustainability has proved successful through the development of plans, and many countries have been able to both introduce new vaccines and mobilize additional financing for immunization, for future GAVI supported vaccine introduction, some country co-financing of these will be needed upfront for the approach to be more sustainable.
authors.affiliation: Immunization Vaccines and Biologicals Department (IVB), Expanded Programme on Immunization (EPI), World Health Organization (WHO), 20 Avenue Appia, CH-1211 Geneva 27, Switzerland. lydonp@who.int
authors.forename: P
authors.initials: P
authors.lastname: Lydon
authors.forename: R
authors.initials: R
authors.lastname: Levine
authors.forename: M
authors.initials: M
authors.lastname: Makinen
authors.forename: L
authors.initials: L
authors.lastname: Brenzel
authors.forename: V
authors.initials: V
authors.lastname: Mitchell
authors.forename: J B
authors.initials: JB
authors.lastname: Milstien
authors.forename: L
authors.initials: L
authors.lastname: Kamara
authors.forename: S
authors.initials: S
authors.lastname: Landry
mesh_terms: D026683:Advisory Committees / Q000191:economics* / Q000458:organization & administration; D016667:Bacterial Capsules / Q000191:economics; D003906:Developing Countries / Q000191:economics; D014943:Global Health; D018073:Haemophilus Vaccines / Q000191:economics; D017048:Health Care Costs / Q000639:trends; D017325:Hepatitis B Vaccines / Q000191:economics; D006801:Humans; D017589:Immunization Programs / Q000191:economics* / Q000458:organization & administration; D007391:International Cooperation; D011634:Public Health
chemical_list: D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D017325:Hepatitis B Vaccines